| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Acrivon Therapeutics, Inc. | Chief Financial Officer | Common Stock | 20,983 | $35,635 | $1.70 | 14 Jan 2026 | Direct |
| Acrivon Therapeutics, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 132,925 | 01 Mar 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics, Inc. | 01 Mar 2026 | 1 | $0 | 4 | Chief Financial Officer | 03 Mar 2026, 16:19 |
| ACRV | Acrivon Therapeutics, Inc. | 14 Jan 2026 | 1 | +$14,999 | 4 | Chief Financial Officer | 16 Jan 2026, 16:01 |
| ACRV | Acrivon Therapeutics, Inc. | 01 Aug 2025 | 1 | -$1,467 | 4 | Chief Financial Officer | 05 Aug 2025, 16:59 |
| ACRV | Acrivon Therapeutics, Inc. | 01 Apr 2025 | 1 | $0 | 4 | Chief Financial Officer | 03 Apr 2025, 16:30 |
| ACRV | Acrivon Therapeutics, Inc. | 01 Apr 2025 | 0 | $0 | 3 | Chief Financial Officer | 03 Apr 2025, 16:28 |